Outpatient non-opioid detoxification for opioid withdrawal. Who is likely to benefit?
The authors examined characteristics of successful completers of an outpatient clonidine/oxazepam detoxification procedure for opioid dependence. Of 215 initial applicants, 167 received medication, and 65 successfully completed by taking a dose of naltrexone. Those who completed were more likely to have last used an opioid other than heroin, to be heroin smokers, rather than intravenous users, to have used benzodiazepines in the 30 days before treatment, and to have abstained from opioids for a longer time before presenting for treatment. New users (for less than 2 years) did no better than those using longer than 2 years. These findings may help in the continued refinement of patient placement criteria.
McCann
M J
MJ
Matrix Center/Los Angeles Addiction Treatment Center, CA 90025, USA.
Miotto
K
K
Rawson
R A
RA
Huber
A
A
Shoptaw
S
S
Ling
W
W
D000293:Adolescent; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage*; D000328:Adult; D000554:Ambulatory Care Facilities; D003000:Clonidine / Q000008:administration & dosage*; D005260:Female; D018757:GABA Modulators / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009271:Naltrexone / Q000008:administration & dosage; D009292:Narcotic Antagonists / Q000008:administration & dosage; D009294:Narcotics; D010076:Oxazepam / Q000008:administration & dosage; D012189:Retrospective Studies; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D019966:Substance-Related Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D018757:GABA Modulators; D009292:Narcotic Antagonists; D009294:Narcotics; D009271:Naltrexone; D010076:Oxazepam; D003000:Clonidine